Replay available

Fate Therapeutics, Inc. (FATE) Q4 2022 Earnings Call

Fate Therapeutics, Inc. (NASDAQ: FATE) Q4 2022 earnings conference call, held 2023-02-28. Replay captured from the company's public earnings webcast.

Tue, February 28, 2023 at 5:00 PMendedReplay
Fate Therapeutics, Inc. (FATE) Q4 2022 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Matthew Begler

Analyst, Oppenheimer

Dr. Bob Ballimer

Chief Research and Development Officer

Ed Duloc

Chief Financial Officer

Ben Burnett

Analyst, Stifel

Dana Gravosh

Analyst, SDB Securities

Andrea Tan

Analyst, Goldman Sachs

Tyler Van Buren

Analyst, Cowan

Michael Schmidt

Analyst, Guggenheim

Michael Yee

Analyst, Jefferies

Robin Karnakis

Analyst

Scott Walshco

President and CEO

Peter Lawson

Analyst, Barclays

Replay transcript excerpt

welcome to the fate therapeutics fourth quarter 2022 financial results conference call at this time all participants are on a listen-only mode this call is being webcast live on the investor section of fate's website at fatetherapeutics.com as a reminder today's call is being recorded i would like to introduce scott walshco president and ceo of fate therapeutics thank you good afternoon and thanks everyone for joining us for the fate therapeutics fourth quarter 2022 financial results call Shortly after 4 p.m. Eastern time today, we issued a press release with these results, which can be found on the investor section of our website under press releases. In addition, our Form 10-K for the year ended December 31, 2022, was filed shortly thereafter and can be found on the investor section of our website under financial information. Before we begin, I'd like to remind everyone that except for statements of historical facts, The statements made by management and responses to questions on this conference call are forward looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward looking statements. Please see the forward looking statement disclaimer on the company's earnings press release issued after the close of market today, as well as the risk factors, including in our Form 10-K for the year ended December 31, 2022, that was filed with the SEC today. Undue reliance should not be placed on forward-looking statements which speak only as the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, Faith Therapeutics disclaim...

More from Fate Therapeutics, Inc.